San Francisco, California, August 31, 2017: The rising incidence of influenza B infection has compelled governments and healthcare organizations to invest in effective therapeutics. A new report by TMR Research, titled “Influenza B Infection Market – Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017 – 2025,” focuses on the same line, gauging prospects for the growth of the market between 2017 and 2025. Various factors enabling growth in the global influenza B infection market are studied in detail. The market share held by various market players are evaluated using industry-leading analytical tools. Besides this, the report identifies factors threatening the market’s trajectory and all this is intended to offer readers a holistic outlook of the global influenza B infection market.
Effective medication and accurate treatment is indispensable for treating influenza B infections and to prevent severe complications. While the market already has several medications and vaccines aimed at influenza B infection, the looming patent expiry of blockbuster drugs and other market forces have impelled key players to focus on research and development of novel and more effective therapeutics for the treatment of influenza B infection. This, coupled with the rising initiatives taken by governments and non-government organizations to spread awareness regarding the condition will accelerate the market’s growth in the coming years.
The report segments the global influenza B infection market based on pipeline assessment, drug class, and regions to provide refined outlook. Regionally, the global market can be segmented into North America, Latin America, Asia Pacific, Europe, and the Middle East and Africa. Factors influencing the market’s trajectory across these segments are discussed in detail. The report finds that nearly 200,000 people require hospitalization in the US on account of complications related to influenza B infection. Such rising incidence of influenza witnessed in the US has put North America as one of the lucrative regional markets for influenza B infection therapeutics and vaccines.
Some of the prominent players operating in the global influenza B infection market are focusing on development novel therapeutics to offer treatment to a wider patient pool around the world. Such steps taken by the market players will provide promising growth opportunities to the market. In addition, the rising healthcare spending and increase in the number of healthcare facilities worldwide, especially in developing countries will enable the market clock an accelerated pace of gains in the coming years.
The presence of a strong pipeline and a large number of market players have made the global influenza B infection market highly competitive. Furthermore, the increasing emphasis on clinical trials is expected to intensify the competition further in the coming years. Moreover, influenza B infection drugs and vaccines are now easily available in the market, which is likely to aid the market’s expansion in the coming years.
The report includes profiles of some of the leading market players to present insights into the prevailing competitive landscape. Some of these companies are Humabs BioMed SA, Autoimmune Technologies, LLC, AltraVax, Inc., REPLICor, Inc., Crucell N.V., ContraFect Corporation, Chimerix, Inc., and Takeda Pharmaceutical Company Limited.
Click on the link below to request a sample copy of the report